Elisabet O. Berge

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik et al. · PLoS ONE · 2008 · 96 citations · Full text

Medicine, Oncology, Pharmacology +16

White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk

Per Eystein Lønning, Elisabet O. Berge, Merete Bjørnslett et al. · Annals of Internal Medicine · 2018 · 53 citations

Medicine, Gynecology, Oncology +17

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

Elisabet O. Berge, Stian Knappskog, Stephanie Geisler et al. · Molecular Cancer · 2010 · 31 citations · Full text

Life Sciences, Genetics, Oncology +16

Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity

Elisabet O. Berge, Vidar Staalesen, Anne Hege Straume et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2010 · 27 citations

Life Sciences, Genetics, Molecular Biology +8

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

Stian Knappskog, Elisabet O. Berge, Ranjan Chrisanthar et al. · Molecular Oncology · 2015 · 24 citations · Full text

Medicine, Genetics, Oncology +17